Target discovery, which incorporates the identification and early validation of disease-modifying targets, is a vital primary step in the drug discovery field. In fact, the need to find out protein function has been motivated, both in industry and academia, since the completion of the human genome project. In this section, we significantly inspect the strategies and methodologies applied for both the identification and validation of disease-relevant proteins. In particular, the likely impact of recent technological advances, including genomics, proteomics, small interfering RNA and mouse knockout models, and conclude by speculating on future trends is examined. Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12â15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It can take several years to construct up a body of supporting data before selecting a target for a costly drug discovery program. Once a target has been chosen, the pharmaceutical industry and more recently some academic centers have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This section will come across at key preclinical stages of the drug discovery procedure, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.
Last date updated on January, 2021